Form D · Biotechnology
Aciex Therapeutics, Inc.
Boston, MA · CIK 0001415518
Offering snapshot reported Apr 24, 2014 · SEC filing
- Reported sold
- $1.6M Offering amount: $3.2M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 17, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 24, 2014 | Initial | $1,599,860 | No comparison | 7 | SEC filing |
| Aug 11, 2011 | Initial | $8,000,000 | No comparison | 1 | SEC filing |
| Oct 12, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-216167
Source: Form D, filed Apr 24, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Abelson | Director |
| Thomas Cavanagh | Executive |
| Les Kaplan | Director |
| Dayton Misfeldt | Director |
| Jake Nunn | Director |
| Raj Rai | Director |
| Hal Werner | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
470 Atlantic Avenue 4th Floor
Boston, MA, 02210
Boston, MA, 02210